Diagnosis & Etiology
Q1 — Diagnostic Criteria Strong · Low
≥2 of the following 3 criteria:
| # | Criterion | Notes |
|---|---|---|
| 1 | Acute upper abdominal pain | Cardinal symptom |
| 2 | Serum lipase or amylase >3× ULN | Lipase preferred; may remain elevated longer than amylase |
| 3 | Imaging: CT or USG showing (peri)pancreatic inflammation ± necrosis | Not required if criteria 1 + 2 are both met |
- <3× ULN does not rule out AP
- >3× ULN can occur in: renal failure, perforated ulcer, macroamylasaemia, gastroenteritis
- Do not monitor serially — enzyme levels do not correlate with disease course
Q2 — Establishing Etiology During Admission Good Practice
History: Gallstone disease, alcohol, medications, hypertriglyceridaemia, trauma, recent ERCP, family history
Labs: LFTs, serum calcium, triglycerides
Imaging: Abdominal USG (biliary system)
Aetiology unidentified in ~20% of cases during hospitalisation → classified idiopathic
- ALT >150 U/L within 48 h → PPV >85% for gallstone AP
- Abnormal LFTs + normal USG → EUS after recovery to exclude microlithiasis
- Tobacco smoking is an independent risk factor (2 systematic reviews)
- Gallstones: ~42% of all AP; Alcohol: ~25–40%
Q3 — Idiopathic AP: Stepwise Workup Strong · Moderate
Age >50 (or younger with risk factors) + no clear aetiology → perform CECT/MRI + EUS to rule out malignancy.
Pancreas divisum: likely a co-factor, not a sole cause. Note that EUS has 64% diagnostic yield vs MRCP 34% when directly compared (7 studies, 249 patients).
Prognostication, Severity & Scoring Systems
Revised Atlanta Classification — Severity Definitions (RAC 2012)
| Severity | Definition | Mortality |
|---|---|---|
| Mild AP | No organ failure; no local or systemic complications | <1% |
| Moderately Severe AP | Transient organ failure (<48 h) AND/OR local or systemic complications without persistent organ failure | ~8% |
| Severe AP | Persistent organ failure (>48 h) — single or multi-organ | 39–42% |
Local complications (Atlanta terminology):
| Collection Type | Timing | Wall | Contents |
|---|---|---|---|
| Acute peripancreatic fluid collection (APFC) | <4 weeks | No | Fluid only |
| Pseudocyst | >4 weeks | Yes | Fluid only |
| Acute necrotic collection (ANC) | <4 weeks | No | Necrosis ± fluid |
| Walled-off necrosis (WON) | >4 weeks | Yes | Necrosis ± fluid |
Modified Marshall Scoring — Organ Failure Assessment
Score ≥2 in any organ system = organ failure. Persistent = >48 h.
| Score | Respiratory PaO₂/FiO₂ (mmHg) |
Renal Creatinine (µmol/L) |
Cardiovascular Systolic BP (mmHg) |
|---|---|---|---|
| 0 | >400 | <134 | >90 |
| 1 | 301–400 | 134–169 | <90, fluid responsive |
| 2 | 201–300 | 170–310 | <90, not fluid responsive |
| 3 | 101–200 | 311–439 | <90, pH <7.3 |
| 4 | ≤101 | >439 | <90, pH <7.2 |
ICU transfer is indicated for grade ≥2 in any organ system (see Section VI). Score does not require all three systems — assess each independently.
Q4 — Bedside Scoring Systems for Severity Prediction
1 point each for:
- BUN >25 mg/dL
- Impaired mental status (GCS <15)
- SIRS — ≥2 of: temp <36 or >38°C, HR >90, RR >20 or PaCO₂ <32, WBC <4 or >12×10⁹/L
- Age >60 years
- Pleural effusion on imaging
HAPS = 0 if ALL present:
- No peritoneal signs (rebound / guarding)
- Normal haematocrit (≤43% F, ≤44% M)
- Normal creatinine (≤2 mg/dL)
HAPS >0: One or more criteria not met.
12-variable composite including: temperature, MAP, HR, RR, oxygenation, arterial pH, Na, K, creatinine, haematocrit, WBC, GCS, age, chronic health.
Calculated within first 24 h of admission.
- IL-6 >50 pg/mL: Sensitivity 87%, Specificity 88% — Best single early predictor
- IL-6 >160 pg/mL: Improves PPV of persistent SIRS from 56% to 85%
- CRP >150 mg/L: Sensitivity 53%, Specificity 82% — Peaks at 48–72 h
All scoring systems perform better as rule-out tools (high NPV) than rule-in tools. Dynamic reassessment at 48 h is essential.
Q5 — Best Outcome Predictor During Admission Strong · High
Persistent organ failure (>48 h) is the single most important determinant of mortality.
- Mortality: 39–42% with persistent organ failure
- Infected necrosis alone does not increase mortality unless combined with organ failure
- Use Modified Marshall Scoring (see above)
Q6 — Transfer to High-Volume Centre Good Practice
Transfer if local expertise is inadequate AND:
- Persistent organ failure
- Infected necrotising pancreatitis
High-volume centres (>118 cases/year) → 25% lower relative risk of death vs low-volume centres.
Imaging in Acute Pancreatitis
Q7 — Indications & Timing of Initial CT Strong · Moderate
Only perform if:
- Diagnostic uncertainty
- Failure to improve with conservative treatment
- Clinical deterioration
TIMING ≥72–96 h after symptom onset to assess severity and detect necrosis fully
- Routine early CT (<72 h) is not recommended
- Full extent of necrosis not apparent before 72–96 h
- CT scores are not superior to clinical scores for prognosis
Early CT is appropriate only when diagnosis is uncertain and other acute abdominal emergencies must be excluded.
Q8 — Follow-up Imaging Good Practice
Indications for repeat CECT:
- Planning invasive intervention
- Clinical deterioration despite conservative management
Prefer MRI when:
- Differentiating pseudocyst vs WON (at ≥3–4 weeks)
- Iodinated contrast allergy or renal failure
- Quantifying necrotic debris before drainage
CT cannot reliably detect necrosis in fluid-predominant collections. MRI T2-weighted sequences are superior for this purpose.
Routine weekly follow-up CT has no evidence base — do not order reflexively.
Q9 — Optimal CT and MRI Technical Protocol Good Practice
CT Protocol:
| Parameter | Specification |
|---|---|
| Scanner | Multidetector CT |
| Slice thickness | ≤2 mm |
| Phases | Pancreatic + portal venous (50–70 s delay) |
| Contrast volume | 100–150 mL non-ionic IV |
| Injection rate | 3 mL/s |
| Follow-up scans | Portal venous phase only (monophasic) is sufficient |
| Pseudoaneurysm suspected | Add arterial phase (dynamic CT) |
Necrosis defined as >1 cm² non-enhancing area with CT value <30–50 HU or <15 HU increase post-contrast.
MRI Protocol:
| Sequence | Use |
|---|---|
| Axial FS-T2W | Standard; detects necrosis without gadolinium |
| Axial FS-T1W | Standard companion sequence |
| Gadolinium contrast | Add if MRI is replacing CECT |
| FS-T2W alone | Sufficient to delineate necrotic vs liquefied components |
- Young patients (radiation burden)
- Renal failure (T2W without contrast)
- Pre-drainage assessment of necrosis ratio
Fluid Therapy
The WATERFALL trial (NEJM 2022) was stopped early: 21% fluid overload in the aggressive arm vs 6% in the moderate arm. Aggressive resuscitation does not prevent necrosis or organ failure — it worsens outcomes.
Q10 — Fluid Choice Strong · Moderate
Lactated Ringer's (LR) solution is preferred over normal saline.
- Reduces systemic inflammation vs normal saline
- Associated with lower severity, ICU admission, and local complications in meta-analyses
- Individual RCT results were mixed and many underpowered — larger trials needed
In AP due to primary hyperparathyroidism with severe hypercalcaemia (Ca >14 mg/dL or altered sensorium): use isotonic saline. Avoid calcium supplements and Vitamin D. LR contains calcium and will worsen hypercalcaemia.
Q11 — Fluid Rate & Strategy Strong · Moderate
Standard rate: 1.5 mL/kg/h. Fluid bolus only for hypovolaemia or hypotension at presentation. Further fluids guided by haematocrit and clinical signs.
Four-Phase Individualised Fluid Therapy Framework
Rescue
Shock / severe hypovolaemia → Fluid bolus for rapid resuscitation
Optimisation
Shock resolving; tissue perfusion at risk → Cautious, titrated to cardiac output
Stabilisation
Haemodynamically stable → Maintenance fluids only
De-escalation
Fluid overloaded → Aim for negative balance; consider diuretics
- Pulmonary oedema and respiratory failure
- Intra-abdominal hypertension / abdominal compartment syndrome
- Worsening organ dysfunction and increased mortality
- Aggressive fluids do NOT prevent pancreatic necrosis — this is definitively established
In severe AP, capillary leak disrupts normal fluid dynamics — standard resuscitation targets may not apply. More caution, not more volume, is required.
Q12 — Monitoring Fluid Response Good Practice
| Parameter | Target | Notes |
|---|---|---|
| MAP | 65–85 mmHg | Heart rate <100/min |
| Urine output | ≥0.5 mL/kg/h | Catheterise if severe |
| BUN | <20 mg/dL (blood urea <40) | Rising BUN at 24 h predicts severity |
| Haematocrit | <44% | Admission Hct 44% + rising BUN → best lab predictor |
| CVP | — | Poor predictor — do not rely on CVP |
Invasive monitoring reserved for ICU patients. Bedside lung ultrasound and IVC assessment are useful in severe AP — apply as in other critically ill patients.
Analgesia
Q13–14 — Pain Assessment & Analgesic Choice Strong · Moderate
Assessment: VAS or NRS — assess periodically throughout admission.
First-line options (equivalent efficacy in mild AP):
- NSAIDs (diclofenac, indomethacin)
- Opioids (morphine, buprenorphine, fentanyl, pentazocine)
Opioids are preferred for severe pain — fewer rescue analgesics required. Supplement with short-acting rescue fentanyl PRN. Patient-controlled analgesia (PCA) is an effective rescue strategy.
- Respiratory depression
- Altered sensorium
- Paralytic ileus
Consider in severe pain with cardiorespiratory comorbidity. A 2023 RCT (EPIPAN, n=148) showed no benefit on ventilator-free days; epidural was associated with longer invasive ventilation. Use selectively.
Organ Failure & ICU Management
Q15 — ICU Admission Criteria Good Practice
Transfer to ICU / high-dependency unit when:
| Indication | Notes |
|---|---|
| Organ failure ≥Grade 2 (Modified Marshall — see Section II) | Primary trigger for ICU admission |
| Infected necrotising pancreatitis with sepsis | Especially MDR organisms |
| Intra-abdominal haemorrhage | Requires intensive monitoring |
| Colonic fistulisation | Septic complication |
| High-risk features: Charlson ≥3, age >65, morbid obesity | Consider HDU even without frank organ failure |
Lactate, CRP, haematocrit, or BUN alone are insufficient. Use clinical gestalt + Modified Marshall scoring.
ICU management follows standard critical care protocols (Surviving Sepsis guidelines). Specific targets: MAP ≥65 mmHg, respiratory support, renal replacement therapy as needed. Monitor intra-abdominal pressure in moderate–severe AP.
Antibiotics
Antibiotic overuse in AP is a documented global problem. Rates as high as 81% in some Asian centres. The evidence-based justified rate is only 20–40%. Antibiotic therapy was not associated with decreased mortality or severity in an international multicenter study of 9,869 patients from 23 countries.
Q17–18 — When to Start Antibiotics Strong · Moderate
TREAT Definite indications:
- Positive microbiological cultures (blood, sputum, bile, urine, drain fluid)
- Gas in peri-pancreatic collections on CT (high specificity for infected necrosis)
- Proven extra-pancreatic infection (cholangitis, pneumonia, UTI)
- Strong clinical suspicion of infected necrotising pancreatitis
DO NOT TREAT Based on these alone:
- Elevated CRP (AUC 0.51 — essentially no discrimination)
- Elevated WBC (AUC 0.45)
- Elevated procalcitonin alone (AUC 0.73 — best biomarker but insufficient sole trigger)
- Fever alone in the first week (SIRS-related, not necessarily infected)
Procalcitonin ≥3.5 ng/mL: Sensitivity 90%, Specificity 89% for infected necrosis. A procalcitonin-guided RCT (PROCAP, n=260) reduced antibiotic use from 63% to 45%. Broader implementation requires further validation in moderate–severe AP.
| Intervention | Recommendation | Grade |
|---|---|---|
| Prophylactic antibiotics (necrotising AP) | NOT recommended | Strong · High |
| Probiotics | NOT recommended — older RCT showed increased bowel ischaemia mortality | Strong · High |
| Selective gut decontamination | NOT recommended | Conditional · Low |
Antibiotic choice for infected necrosis: 3rd/4th generation cephalosporins, carbapenems, ureidopenicillins, or quinolones — all penetrate pancreatic tissue. Tailor to local sensitivity profiles and cultures. Single broad-spectrum agent generally preferred unless Pseudomonas is suspected.
Nutritional Support
Prolonged fasting in AP is obsolete. Early oral/enteral feeding reduces complications, mortality, and hospital stay across all severity grades.
Nutrition Pathway by Severity and Tolerance
Low-fat solid diet — as safe as clear liquids (multiple RCTs)
Early refeeding reduces length of stay; does not increase pain relapse
Strong · Moderate
Nasogastric route is acceptable as first choice
EN within 48 h → Reduced mortality, organ failure, and infection (meta-analyses)
Strong · High
Both routes are equivalent in safety and efficacy. Nasojejunal is required — not merely preferred — when patients have persistent vomiting, gastric outlet obstruction, or gastric ileus. Strong · High
Polymeric formulas are recommended. Semi-elemental and elemental formulas show equivalent clinical outcomes and are more expensive. Immunonutrition and omega-3 supplementation are not recommended — insufficient evidence. Conditional · Moderate
If PN is required in hypertriglyceridaemic AP: withhold IV fat emulsion when TG ≥400 mg/dL.
Biliary Tract Management, ERCP & PEP Prevention
Q28 — Early ERCP in Acute Biliary Pancreatitis (within 72 h)
| Clinical Scenario | Early ERCP/ES? | Grade |
|---|---|---|
| Mild biliary AP without cholangitis | NOT recommended | Strong · High |
| Predicted severe biliary AP without cholangitis | NOT recommended | Strong · Moderate |
| Any biliary AP with acute cholangitis | RECOMMENDED | Strong · High |
| Cholecystectomy not feasible same admission | Consider ERCP/ES to prevent recurrence | Conditional · Low |
Diagnosing cholangitis in the context of SIRS is challenging — apply clinical judgement. An EUS-guided strategy for urgent ERCP showed no benefit in the absence of cholangitis.
Q29 — CBD Stone in Biliary AP without Cholangitis Strong · High
- CBD stone confirmed on EUS or MRCP → Elective ERCP/ES is indicated
- CBD stone alone does not justify urgent ERCP without cholangitis
- All biliary AP patients have ≥intermediate risk of choledocholithiasis — perform MRCP, EUS, or intraoperative cholangiography before cholecystectomy unless CBD stone already clearly visible
Post-ERCP Pancreatitis Prevention — Q68–71
Rectal NSAIDs are now recommended for all patients undergoing ERCP — not only high-risk. Universal prophylaxis is the standard of care.
| Intervention | Recommendation | Grade |
|---|---|---|
| Rectal indomethacin or diclofenac | All patients — give ≤30 min before procedure | Strong · High (high-risk) · Moderate (average-risk) |
| Periprocedural IV LR (moderate volume) | In addition to rectal NSAIDs | Strong · Moderate |
| Prophylactic pancreatic duct stent | If inadvertent multiple PD cannulation or PD contrast injection | Conditional · Moderate |
| PD stent + rectal NSAID (combined) | Consider in high-risk patients — additive benefit demonstrated | Conditional · Moderate |
The FLUYT trial (Lancet Gastroenterol Hepatol 2021) showed that aggressive IV fluid hydration on top of rectal NSAIDs provides no additional reduction in PEP compared to standard fluids + rectal NSAIDs. Moderate LR is sufficient; do not over-hydrate for PEP prevention.
5-Fr diameter, 3–5 cm long, single pigtail without internal flanges. Remove within 2–3 weeks if not spontaneously passed. Failed PD stent placement can itself increase PEP risk.
Conservative Management of Necrotising Pancreatitis
Q30 — Sterile Necrotising AP Strong · Low
- Up to 80% of necrosis remains sterile — conservative treatment is appropriate for the majority
- Analgesia + enteral nutrition + ICU support (if indicated)
- No role for octreotide, somatostatin, protease inhibitors, or antisecretory agents
- Early necrotic collections are not amenable to effective drainage — do not intervene prematurely
- 2nd–4th week: period of watchful observation for development of secondary infection
Q31 — Diagnosing Infected Necrotising Pancreatitis (INP) Strong · Low
Suspect INP when (typically after 7–10 days):
- New or persistent fever
- Rising WBC or procalcitonin
- Clinical deterioration or sepsis features
Radiological clue: Gas bubbles in (peri)pancreatic necrosis — high specificity, moderate sensitivity
PCT ≥3.5 ng/mL: Sensitivity 90%, Specificity 89% for infected necrosis
- False-negative rate: 20–29%
- False-positive rate: 4–10%
- Risk of introducing exogenous infection
Reserve FNA for: no clinical response to broad-spectrum antibiotics AND suspicion of MDR or fungal infection.
Up to 20% of AP patients develop extra-pancreatic infections (bacteraemia, pneumonia, UTI) — exclude these when interpreting elevated inflammatory markers before attributing to INP.
Q32–35 — Initial Treatment of Suspected INP Strong · Low
Begin with IV broad-spectrum antibiotics + optimal enteral nutrition. Two-thirds of patients can avoid surgical necrosectomy with this strategy. A key RCT showed 39% of patients in the postponed drainage group were managed with antibiotics alone — no drainage or necrosectomy required.
Defining treatment failure:
- Persistent fever + leukocytosis despite targeted antibiotics, OR
- Clinical worsening with development of sepsis
No reliable serological or radiological markers predict failure within a defined timeframe — monitor daily.
Antifungal therapy:
- Prophylactic / empirical antifungals: NOT recommended
- Fungal infection in ~26.6% of necrotising AP — high mortality (OR 3.95)
- Treat confirmed or highly suspected invasive infection only
- Preferred agent: echinocandin
- Distinguish colonisation from invasive infection
Interventions — Step-Up Approach Algorithm
Q36 — Indications for Intervention
Common indications:
- INP with clinical deterioration (preferably when walled-off)
- Symptomatic sterile WON: pain, gastric outlet obstruction, biliary obstruction, nutritional failure
Less common: Pancreatic haemorrhage · Bowel ischaemia · Fistula
Massive haemorrhage · Perforated hollow viscus · Ischaemic bowel
Q37–44 — Step-Up Algorithm
Broad-spectrum IV antibiotics (if INP suspected) + Optimal enteral nutrition + ICU support
Percutaneous catheter drainage (PCD) — Required for paracolic, pelvic, retrocolic collections. Multiple catheters possible; retroperitoneal access.
Both are equivalent first-line options — choose by collection location and local expertise. Resolves 40–60% of cases without further escalation.
Minimally invasive retroperitoneal necrosectomy / VARD — After PCD via retroperitoneal route. Single-stage with continuous postoperative drainage.
Transgastric surgical necrosectomy (laparoscopic or open) — WON in lesser sac; effective single-stage procedure with durable internal drainage; preferred when significant necrosis + biliary aetiology.
Remove only loosely adherent necrosis — do not disturb adherent tissue; residual liquefies and resorbs.
Mortality: ~10% after 28 days from onset; >50% if multiple risk factors present.
- Both acceptable for WON drainage
- Prefer LAMS: Infected WON or necrotic debris >30% of collection
- Coaxial DPPS inside LAMS → reduces occlusion risk
- Post-LAMS DPPS reduces recurrence but not reintervention rate
- Network meta-analysis (28 studies, 2,974 patients): LAMS superior to multiple DPPS
May be considered in clinically stable, well-encapsulated collections. A 2024 RCT (DESTIN, n=70) showed fewer reinterventions vs step-up approach. Avoid in unstable patients or poorly demarcated collections. Conditional · Low
Acute Non-Infectious Complications
Intra-abdominal Hypertension (IAH) & Abdominal Compartment Syndrome (ACS) — Q45–48
| Condition | Definition | Incidence in AP |
|---|---|---|
| IAH | Sustained IAP ≥12 mmHg (via urinary bladder — 25 mL sterile saline instillation) | ~17% overall; higher in severe AP |
| ACS | IAP >20 mmHg + new/progressive organ dysfunction (± abdominal perfusion pressure <60 mmHg) | Associated with 49% mortality |
Management of IAH Conditional · Low:
- Percutaneous drainage of ascites / fluid collections (↓IAP ~2 mmHg; more in ACS with large ascites)
- Adequate analgesia
- Enteral decompression (NG or rectal tube)
- Avoid positive cumulative fluid balance
Consider laparotomy if: worsening organ dysfunction AND all non-operative measures have failed. With early decompression, mortality reduced from 49% to 18% (retrospective). Risk: entero-atmospheric fistula, inability to close abdomen.
Haemorrhagic Complications — Q49
Epidemiology: Incidence 0.5–1.2%; after PCD: 4–16%. Median onset ~59 days post-AP.
Causes: 60% pseudoaneurysm · 20% haemorrhage into pseudocyst · 20% small vessel
Most common site: Splenic artery (35–50%), then gastroduodenal and pancreaticoduodenal vessels
Risk factors: Persistent organ failure (HR 2.3), large-bore catheter >20 Fr (HR 3.9), >50% necrosis (HR 3.1)
Angioembolisation — First-line; success 88–100%
If fails: Percutaneous thrombin/gelfoam injection (non-catheterisable pseudoaneurysm) or EUS-guided embolisation
Surgery if non-surgical methods fail (ligation, resection, packing)
Diagnosis: Triple-phase CT. Mortality: 11–38%.
Splanchnic Venous Thrombosis (SVT) — Q50–51
| Scenario | Recommendation | Grade |
|---|---|---|
| Isolated splenic vein thrombosis | No anticoagulation — high spontaneous recanalization rate | Conditional · Low |
| Extensive SVT (portal or mesenteric vein involvement) | Anticoagulation may be used | Conditional · Low |
Recanalization with anticoagulation: 44.3%. No survival benefit; marginal increase in bleeding risk. (Systematic review, 16 studies, n=698). Diagnosis: CECT is most appropriate modality.
Bowel Fistula — Q52–54
Incidence: 10–15% of necrotising AP. Sites: Colon > duodenum > stomach > small intestine.
Usually resolves spontaneously. May facilitate internal drainage of PFCs. No active treatment typically required. Conditional · Low
Conservative first: infection control + nutrition. Surgery required if: persistent/worsening infection, peritonitis, or faecal discharge from peripancreatic collection. Conditional · Low
Special Types of Acute Pancreatitis
Hypertriglyceridaemia-Associated AP (HTGP) — Q64–67
- Up to 10% of all AP; 2nd leading cause in China
- Often more severe: higher rates of SIRS, organ failure, and mortality
- Pathogenesis: chylomicron excess → capillary ischaemia/acidosis; free fatty acids → acinar cell injury
TG reduction — acute phase:
- Insulin — First-line. Diabetics: recommended. Non-diabetics: may consider. Enhances LPL activity and TG clearance. Strong · Moderate
- Short-term LMWH (<3 days) — May be considered. Long-term heparin depletes LPL. Conditional · Moderate
- Plasmapheresis — Persistent organ failure + very high TG, especially with renal failure. No clear benefit on organ failure duration in prospective cohort. Use selectively. Conditional · Low
Nutrition in HTGP:
- Fast for first 48 h — reduces TG rapidly Strong · Low
- Then low-fat soft diet; EN via NG/NJ if oral not tolerated
- If PN required: withhold IV fat emulsion if TG ≥400 mg/dL Strong · Low
Post-discharge TG target: <500 mg/dL Conditional · Low
Fenofibrate most used; no RCT proves it prevents recurrence. Newer agents (volanesorsen, olezarsen targeting APOC3) shown to reduce pancreatitis recurrence in familial hypertriglyceridaemia.
The TG <500 mg/dL post-discharge target is a Conditional recommendation, low-quality evidence — frequently misquoted as strong.
Traumatic Pancreatitis — Q72–75
| Scenario | Recommendation |
|---|---|
| Haemodynamically stable | CECT first. If CT equivocal → MRI/MRCP. If persistent suspicion + initial CT <12 h → repeat CT at 24–48 h |
| ERCP in trauma | NOT for diagnosis — therapeutic only (MPD stenting if indicated) |
| Grade 1–2 injury | Conservative management |
| Grade 3 injury (stable) | Early distal pancreatectomy |
| Haemodynamically unstable | Exploratory laparotomy — damage control approach |
| Symptomatic MPD disruption (stable, non-surgical) | ERCP + pancreatic stenting (transpapillary 5 Fr stent bridging injury) |
Acute Pancreatitis in Pregnancy — Q76–79
Incidence: 1 in 10,000 pregnancies. Most common cause: gallstones.
Fetal risks: Preterm delivery (17.9%), perinatal mortality including intrauterine death. Worst in 1st trimester and severe AP.
Imaging:
- USG — First-line
- MRI (without gadolinium) — If USG inconclusive; safe in all trimesters
- CT: Dose ~0.01 Gy — below 0.05–0.15 Gy fetal harm threshold, but minimise use
Management: Same as non-pregnant. Consult obstetrics.
Recommend for mild acute biliary pancreatitis.
Preferred timing: 2nd trimester or early 3rd trimester.
Recurrence during pregnancy: up to 70% vs 20–30% in general population — early surgery is critical.
Laparoscopic cholecystectomy is safe in all trimesters.
Left pelvic tilt / left lateral position. Fetal monitoring. Minimise fluoroscopy; lead abdominal shield; avoid hard-copy X-ray films.
Targeted Therapy
Q80–81 — Current Status Good Practice
All pharmacological agents tested to reduce severity have failed: lexipafant, pentoxifylline, protease inhibitors (ulinastatin, gabexate, nafamostat), somatostatin, octreotide, and continuous regional arterial infusion. No targeted therapy can be recommended.
Agents currently in active clinical trials: ORAI1 channel inhibitor · omega-3 fatty acids · tocilizumab (anti-IL-6R) · steroids · infliximab (anti-TNF-α) · low-molecular-weight heparin · COX-2 inhibitors (parecoxib → imrecoxib showed promise in one 2025 RCT).
A platform master protocol with adaptive design, analogous to cancer precision medicine, is proposed to accelerate drug development. Patient-reported outcomes are increasingly required by FDA for AP trial approval.
Discharge Criteria
Q82 — Clinical Criteria for Safe Discharge Conditional · Low
All of the following should be met:
- Haemodynamically stable
- Tolerating oral diet (preferably solid food)
- Improving CRP and/or WBC
- No persistent fever
- Minimal or no non-opioid analgesia required
- Ongoing nausea, vomiting, diarrhoea at discharge
- Tolerating less than solid diet
- Moderate to heavy alcohol use
- Presence of pancreatic necrosis
Q83 — Scoring Tools for Discharge Decisions Conditional · Low
No validated scoring system is recommended for mandatory use. The following may guide clinical judgement:
| Score | Components | Interpretation |
|---|---|---|
| SNAPP | Symptoms · Nutrition (less than solid diet) · Antibiotic use · Pancreatic necrosis · Pain at discharge | High score → 68% readmission; Low score → 4% readmission. Externally validated. |
| PASS | Morphine equivalents · Oral tolerance · Solid food tolerance · Pain VAS · Activity level (0–400 points) | PASS >60 → Sensitivity 68%, Specificity 71% for 30-day readmission. |
Readmission occurs in >20% after first episode and strongly correlates with 1-year mortality. Late readmission (>30 days) is strongly associated with alcohol use — target modifiable behaviour.
Prevention of Recurrent Acute Pancreatitis
Q84–86 — Cholecystectomy Timing
| Scenario | Recommendation | Grade |
|---|---|---|
| Mild acute biliary pancreatitis | Same-admission cholecystectomy — reduces recurrence from 9% → 2% | Strong · Moderate |
| Moderate / severe AP with necrotising pancreatitis and/or PFCs | Delay until collections nearly resolve | Conditional · Low |
| PFCs persisting >6 weeks | Time by inflammation resolution; may combine with surgical drainage | Conditional · Low |
| Post-ERCP + ES, fit for surgery | Cholecystectomy recommended | Conditional · Moderate |
| High surgical risk post-ES (elderly, comorbidities) | ES alone is reasonable; risk of recurrent biliary colic persists | — |
Target cholecystectomy within 8 weeks of discharge in necrotising biliary AP to minimise recurrence (retrospective data). Same-admission cholecystectomy also reduces post-pancreatitis diabetes and improves patient-reported outcomes.
Long-Term Complications & Follow-Up
Q87–91 — Structured Post-Discharge Follow-Up Strong · Moderate
| Complication | Prevalence / Risk | Action |
|---|---|---|
| Recurrent AP | Up to 1/3 of patients | Eliminate treatable causes: alcohol, smoking, TG, structural lesions |
| Chronic pancreatitis | ~10%; 4× higher risk in men, alcohol aetiology, recurrent AP | Monitor; smoking cessation critical |
| Diabetes mellitus | 23% after first AP (pooled); 39% after severe AP; 37% after necrotising AP | HbA1c + fasting glucose: start at 3–6 months, then annually Strong · Moderate |
| Pancreatic exocrine insufficiency (PEI) | 35% at 36 months; 62% during hospitalisation | PERT if steatorrhoea or fecal elastase <100 µg/g Conditional · Moderate |
| Pancreatic cancer | HR 2.02 at >5 years (association debated) | Consider surveillance if age >50 and no clear aetiology identified |
| Quality of life / mental health | Significantly impaired in necrotising AP | Psychological support; address pain and nutrition Good Practice |
| Premature mortality | 3× higher vs general population up to 8 years post-AP | Regular follow-up; manage comorbidities aggressively |
Disconnected Pancreatic Duct Syndrome (DPDS)
Q92–96 — Overview, Diagnosis & Management
Definition: Complete main pancreatic duct disruption by central necrosis, disconnecting secreting upstream tissue from the GI tract.
Incidence: 10–75% of necrotising AP. Most patients remain asymptomatic (only ~13% require intervention).
Presentations:
- Persistent external pancreatic fistula (EPF)
- Recurrent pseudocyst / PFC
- Recurrent AP in upstream gland (uncommon)
Diagnosis:
- Acute phase: CECT (central necrosis suggests DPDS)
- Post-acute: MRCP preferred
- EUS: Assesses viable disconnected tissue
- ERCP: Cannot reliably distinguish stenosis from disconnection
Indications for intervention:
- High-output EPF (>200 mL/day) — persistent
- Symptomatic recurrent PFCs (pain, infection, obstruction)
- Recurrent AP in upstream gland
<200 mL/day: Often self-limiting due to upstream gland atrophy. Trial 2–3 months: nasojejunal feeding + high-dose pancreatic enzymes + downsize PCD.
Endoscopic management (fewer fistulas than percutaneous or surgical). Endoscopic transluminal drainage, plastic stents, EUS-guided pancreaticogastrostomy. Surgical options (left pancreatectomy or Roux-en-Y) → ~90% durable response.
Major Changes vs Older Practice
The 2025 IAP guidelines represent a definitive shift away from aggressive intervention toward a conservative-first, minimally invasive, individually-tailored approach. Less fluid. Less antibiotics. Earlier feeding. Delayed, endoscopy-preferred drainage. These are not merely incremental updates — they reflect a decade of level-1 evidence fundamentally changing AP management.
Source: IAP/APA/EPC/IPC/JPS Working Group. International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025. Pancreatology 2025. https://doi.org/10.1016/j.pan.2025.04.020
This is an optimised educational summary for self-study. All factual errors from the source highlights have been corrected (Q8 reference, Q31 PCT cutoff, Q44 labelling, Q64 RCT citation, Q67 recommendation strength). Clinical decisions must be made in the context of individual patient circumstances and local institutional expertise.